Nasdaq

Purple Biotech Advances Phase 2 Study of NT219 in Combination with Keytruda and Erbitux for Head and Neck Cancer Patients

Purple Biotech Ltd. announced it is advancing NT219, a novel drug aimed at overcoming tumor resistance to therapy, into a Phase 2 clinical trial for patients with recurrent/metastatic squamous cell ...
Nasdaq

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech ...
Seeking Alpha

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer Purple Biotech’s NT219 is a first-in-class small molecule drug designed to ...